global biopharma faces local innovation, price wars and collective procurement, but given aging, rising middle-class demand and tech leadership, long-term growth prospects remain robust
I agree with your analysis. The transition from isolated AI demos to integrated clinical infrastructure is where real defensibility is built. Workflow friction and EHR integration latency remain the primary bottlenecks on the ground.
I agree with your analysis. The transition from isolated AI demos to integrated clinical infrastructure is where real defensibility is built. Workflow friction and EHR integration latency remain the primary bottlenecks on the ground.